Raymond James Financial Inc. purchased a new position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 20,382 ...

Across the recent three months, 11 analysts have shared their insights on argenx ARGX + Free Alerts , expressing a variety of ...

KLP Kapitalforvaltning AS purchased a new position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund purchased 10,800 shares of ...

Immunovant stated that these changes are part of its parent entity, Roivant, increasing operational involvement and strategic ...

The company announced this month that it confirmed the efficacy of batoclimab in phase 3 clinical trials for myasthenia gravis and phase ... trial results for thyroid eye disease in the second ...

Aline Browning set out to find answers when her father died from lung cancer following a 25-year career at what was once Lackawanna County’s largest employer. “My dad was not ready. He had ...

Its product portfolio comprises Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which treat psoriasis, atopic dermatitis, thyroid eye disease ... that treats myasthenia gravis and chronic ...

The patient denied any family history of myasthenia gravis, other autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, and autoimmune thyroid disease), or neuromuscular ...

Furthermore, there was no history of thyroid disease, and her current thyroid function ... or psychological factors contributing to myasthenia gravis cannot be completely excluded. This case ...

Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients ...